PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Vincristine

Drugs in development · updated 30 October 2026

Vincristine: clinical trials and development status

Other names and codes: Marqibo Kit

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Vincristine is in 217 active clinical trials (recruiting or ongoing, phases I–III) for 77 diseases. The most advanced phase is III.

217Active trials
IIIMost advanced phase
77Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Vincristine and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 77 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Precursor lymphoblastic lymphoma/leukemiaIII30NCT03007147
Diffuse large B-cell lymphomaIII29NCT06717347
Burkitt lymphomaIII25NCT02101853
Follicular lymphomaIII16NCT06091254
LymphomaIII16NCT04529772
RhabdomyosarcomaIII14NCT02567435
B-cell lymphomaIII13NCT04529772
Acute biphenotypic leukaemiaIII9NCT03007147
NeoplasmIII9NCT04529772
Precursor T-cell lymphoblastic leukemiaIII9NCT02112916
Ewing sarcomaIII7NCT02306161
NeuroblastomaIII7NCT06172296
Non-Hodgkin lymphomaIII7NCT04529772
Precursor B-cell lymphoblastic leukemiaIII7NCT03914625
Hodgkin lymphomaIII6NCT00379041
Peripheral T-cell lymphomaIII6NCT06947967
LeukemiaII–III5NCT03117751
Lymphoma, B-Cell, Marginal ZoneIII5NCT06006117
MedulloblastomaIII5NCT05382338
RetinoblastomaII–III5NCT04681417
Down syndromeIII3NCT03914625
Embryonal rhabdomyosarcomaIII3NCT02567435
HepatoblastomaIII3NCT03533582
Lymphoproliferative disordersIII3NCT04529772
Alveolar rhabdomyosarcomaIII2NCT02567435
AstrocytomaIII2NCT00887146
CardiotoxicityIII2NCT06220032
GanglioneuroblastomaIII2NCT06172296
GliomaIII2NCT00887146
Central nervous system neoplasmIII1NCT00887146

Everything on Vincristine

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch